Vident Advisory’s Pacira BioSciences PCRX Stock Holding History

Vident Advisory’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$765K	Sell	30,157 -3,956	-12%	-$93.5K	0.01%	1129
2026 Q1	$771K	Buy	34,113 +10,542	+45%	+$234K	0.01%	996
2025 Q4	$610K	Buy	23,571 +3,075	+15%	+$73.1K	0.01%	1053
2025 Q3	$528K	Buy	20,496 +2,255	+12%	+$55.4K	0.01%	1180
2025 Q2	$436K	Sell	18,241 -2,078	-10%	-$52.4K	﹤0.01%	1142
2025 Q1	$505K	Sell	20,319 -9,035	-31%	-$216K	0.01%	1027
2024 Q4	$553K	Sell	29,354 -1,493	-5%	-$26.2K	0.01%	889
2024 Q3	$464K	Buy	+30,847	New	+$527K	0.01%	963

Other funds holding PCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vident Advisory's PCRX Position: Q2 2026 in Review

Vident Advisory reduced its Pacira BioSciences (PCRX) stake by 12% in Q2 2026, selling an estimated $93.5K and leaving 30,157 shares worth $765K. The position accounts for 0.01% of the portfolio, ranked #1129.

Vident Advisory first reported a position in PCRX in Q3 2024 and has held it in 8 quarters since. The position peaked at $771K in Q1 2026. 253 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

Vident Advisory held 30,157 shares of Pacira BioSciences worth $765K as of Q2 2026.
Vident Advisory sold 3,956 Pacira BioSciences shares in Q2 2026, an estimated $93.5K.
Pacira BioSciences made up 0.01% of Vident Advisory's portfolio in Q2 2026, its #1129 holding.
Vident Advisory first reported a position in Pacira BioSciences in Q3 2024 and has held it in 8 quarters since.
Vident Advisory's Pacira BioSciences position peaked at $771K in Q1 2026.
253 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on Vident Advisory's 13F filing for Q2 2026, filed 12 Aug 2026.